FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Hybrid Stent Graft, Thoracic Aortic Lesion Treatment
PMA: P210006
·
Supplement: S010
·
Decision Mar 28, 2025
Classifications
1
FEI Numbers
3
Registration Numbers
3
Basic Information
- Device Name
- Hybrid Stent Graft, Thoracic Aortic Lesion Treatment
- Trade Name
- Thoraflex Hybrid
- PMA Number
- P210006
- Supplement Number
- S010
- Device Class
- FDA Class 3
- Product Code
- QSK
- Generic Name
- Hybrid stent graft, thoracic aortic lesion treatment
- Medical Specialty
- Unknown
- Advisory Committee
- Cardiovascular
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- March 28, 2025
- Date Received
- July 10, 2024
- Supplement Type
- Normal 180 Day Track
- Supplement Reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Expedited Review
- N
Advisory Committee Statement
approval for a change in the supplier of the bovine gelatin used to impregnate the grafts, implementation of a new sterilization suite, delivery system material changes, shelf-life updates, and other manufacturing changes.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| QSK | Hybrid Stent Graft, Thoracic Aortic Lesion Treatment | FDA class 3 | Unknown |